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Abstract
Androgens, steroid hormones produced by follicular cells, play a crucial role in the regu-
lation of ovarian function. They affect folliculogenesis directly through androgen recep-
tors (ARs) or indirectly through aromatization to estrogens. Androgens are thought to be 
primarily involved in preantral follicle growth and prevention of follicular  atresia. It also 
seems possible that they are involved in the activation of primordial follicles. According 
to the World Health Organization, endocrine-disrupting chemicals (EDCs) are substances 
that alter hormonal signaling. EDCs comprise a wide variety of synthetic or natural chemi-
cals arising from anthropogenic, industrial, agricultural, and domestic sources. EDCs inter-
fere with natural regulation of the endocrine system by either  mimicking or blocking the 
function of endogenous hormones as well as acting directly on gene expression or through 
epigenetic modifications. Disruptions in ovarian processes caused by EDCs may originate 
adverse outcomes such as anovulation, infertility,  or premature ovarian failure. In this 
chapter, we aim to point out a possible involvement of androgen excess or deficiency in 
the regulation of ovarian function. We will summarize the effects of EDCs expressing anti-
androgenic or androgenic activity on female physiology. Continuous exposition to even 
small concentration of such compounds can initiate oncogenesis within the ovary.
Keywords: androgens, androgen receptors, ovarian follicle, folliculogenesis, endocrine-
disrupting chemicals
1. Introduction             
The mammalian ovarian follicle guarantees two essential functions in the ovary. It synthe-
sizes many substances, including steroids, and by this way creates a microenvironment for 
the proper development and maturation of a viable oocyte. Even though gonadotrophins are 
© 2017 The Author(s). Licensee InTech. This chapter is distributed under the terms of the Creative Commons
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regarded as the main hormones regulating follicular development, sex steroids are also known 
to play an important role in this process. Currently, the least established follicular function is 
that related to androgens. Androgens were originally regarded as hormones influencing pri-
marily the male physiology. This perception has changed as numerous investigations have 
demonstrated the effects of androgens such as testosterone (T) and dihydrotestosterone (DHT) 
on female physiology [1]. It turned out that androgens are one of the most important agents 
influencing folliculogenesis [2–6]. Androgens are known to exert pro-apoptotic effects [7, 8] 
but are also indispensable in normal folliculogenesis for both androgen receptor-mediated 
responses and as substrates for estrogen synthesis [9]. Androgenic actions play a role mainly 
in early follicular growth, whereas estrogenic roles are more important at later follicle devel-
opment stages [1, 9]. The high number of androgen receptors (ARs) that characterize granu-
losa cells (GCs) in preantral follicles declines during antral differentiation at the same time as 
expression of mRNA for P450 aromatase (P450arom) and estrogen synthesis increase [10–13].
Recently, a growing concern aroused about the potential for environmental endocrine- 
disrupting chemicals (EDCs) to alter sexual differentiation. EDCs are one of the factors that 
can induce unfavorable changes taking place in the ovary [14, 15]. They originate as a result 
of human industrial activities, enter the natural environment, and then disturb hormonal 
regulation (e.g., through blocking steroid hormone receptors) [16]. Such a mechanism of 
action negatively influences many processes taking place in the reproductive tract of a female 
[17, 18]. In extreme cases, this may lead to the elimination of many populations from their 
natural habitats, by premature cessation of ovarian function, among other putative mecha-
nisms. The image of muscular bodies as the model for an ideal, which is frequently carried 
in mass communication media, has led to an increase in the number of enthusiasts for andro-
genic anabolic steroid (AAS) use. AAS is a group of synthetic compounds that originate from 
testosterone and its esterified or alkalinized derivatives belonging to EDCs. The association 
between AAS use and cancer that has been described in the literature and may be related to 
the genotoxic potential has already been shown in several studies [19, 20]. In vitro toxicologi-
cal models are widely used to assess the effects of endogenous androgens and EDCs on ovar-
ian function, to understand their role in the initiation/progression of ovarian cancers.
In this chapter, we intend to point out a possible impact of androgen excess or deficiency on the 
regulation of ovarian function as well as following EDC action with antiandrogenic (e.g., vinclo-
zolin, linuron) or androgenic (e.g., anabolic steroids: testosterone propionate, boldione) activity 
due to the fact that continuous exposition to even small concentration of such compounds can 
initiate oncogenesis within the ovary. Following our previous results obtained using an in vitro 
animal model generated for studying androgen deficiency, we have found that the exposure of 
porcine follicles to an environmental antiandrogen—vinclozolin—caused deleterious effects at 
antrum formation stage that may negatively influence the reproductive function in mammals.
2. Androgen receptor structure and mechanism of action
Like all steroid hormones, androgens affect target cells by binding to and activating special-
ized receptors. The types of receptors that are involved in the signal transduction decide on 
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its mechanism of action. A genomic response is usually induced by receptors localized in 
the cytoplasm/nucleus. Additionally, androgens can also exert their effects by interacting 
with receptors located on the cell membrane to perform rapid, non-genomic actions. It is well 
known that the cross talk between non-genomic and genomic signaling pathways is crucial 
for proper ovarian function [21].
The ARs, encoded by a gene composed of eight exons located on the X chromosome, are 
proteins with approximately 919 amino acids. The exact length of ARs is variable due to the 
existence of two diverse polyglutamine and polyglycine stretches in the N-terminal region 
of the protein [22]. This AR region modulates its transactivation [23, 24] and, hence, its func-
tionality. The ARs, which belong to the nuclear receptor superfamily, are characterized by a 
modular structure consisting of four functional domains: C-terminal domain responsible for 
ligand binding (LBD), a highly conserved DNA-binding domain (DBD) with centrally located 
zinc fingers, a hinge region, and N-terminal domain (NTD) (Figure 1) [25, 26]. The C-terminal 
domain of ARs is encoded by exons 4–8. Within itself, besides LBD, C-terminal domain also 
contains transcriptional activation function 2 (AF2) co-regulator binding interface [27, 28]. 
In the most conserved region of ARs—DNA-binding domain—two zinc fingers encoded by 
exon 2 and exon 3, respectively, are located. The first zinc finger determines the specificity of 
DNA recognition, which makes contact with major groove residues in an androgen-response 
element (ARE) half-site. The second zinc finger is a dimerization interface that mediates bind-
ing with a neighboring AR molecule engaged with an adjacent ARE half-site [29]. The short 
flexible hinge region, encoded by exon 4, regulates DNA binding, nuclear translocation, and 
transactivation of the ARs [30]. The N-terminal domain, encoded by AR exon 1, is relatively 
long and poorly conserved. It displays the most sequence variability by, as mentioned above, 
virtue of polymorphic (CAG)n and (GGN)n repeat units encoding polyglutamine and poly-
glycine tracts, respectively [31–33]. This domain contains also the AF1, which harbors two 
transactivation regions, transcriptional activation unit-1 (TAU-1), and transcriptional activa-
tion unit-5 (TAU-5). The N-terminal domain is essential for AR activation [34] and, because 
it contains many sites for Ser/Thr phosphorylation, may be involved in mediating cross talk 
with other signaling pathways leading to the modulation of AF1 activity and interaction with 
co-regulators [35].
In the absence of androgens, unliganded ARs remain in the cytoplasm. To maintain the unbounded 
AR protein in a stable and inactive configuration, the molecular chaperone complex, including 
Hsp90 and high-molecular-weight immunophilins, is needed. Androgens like other steroids can 
freely diffuse across the plasma membrane and bind to the LBD region that induces conforma-
tional changes, including the Hsp90 dissociation from ARs. Followed by these transformation, 
ARs undergo dimerization, phosphorylation, and translocation to the nucleus, which is mediated 
by the nuclear localization signal (NLS) in the hinge region. The dimer binds to the androgen 
response elements (AREs) located in the promoter of the target gene and leads to the recruit-
ment of co-regulators, either coactivators or corepressors such as steroid receptor coactivator 1 
(SRC1) and transcriptional intermediary factor 2 (TIF2), leading to transcription of genes that 
are involved in many cellular activities, from proliferation to programmed cell death [36]. In 
some cases, for example, in the low androgen concentration, the ligand-independent signaling 
pathway may occur. This process involves MAPK/ERK pathway and depends on growth factor 
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receptors. As a result, transcriptional activity enhancement, through direct phosphorylation of 
steroid receptors, is observed [37]. The androgen signaling pathways depicted above are collec-
tively known as “genomic pathway” (Figure 2) [38].
Apart from the direct or indirect genomic effects, androgens may also operate in cells by the 
“non-genomic pathway,” stimulating rapid effects in signal transduction through the produc-
tion of second messengers, ion channel transport, and protein kinase cascades. This kind of 
activity involves receptors localized in the plasma membrane or in “lipid rafts” [39]. Rapid 
non-genomic action of androgens might be mediated by binding to transmembrane recep-
tors unrelated to nuclear hormone receptors (usually G-protein-coupled receptor (GPCR)) 
that was well documented in different tissues [40, 41]. Among GPCRs, there are GPRC6A 
and ZIP9 that have been pharmacologically well characterized [42, 43]. Additionally, andro-
gens can induce activation of the Src/Ras/Raf/MAPK/ERK1/ERK2 pathway in the cytoplasm, 
independently of receptor-DNA interactions (Figure 2) [44, 45]. It was shown that in lutein-
ized human GCs androgens caused rapid, non-genomic-dependent rise in cytosolic calcium, 
involving voltage-dependent calcium channels in the plasma membrane and phospholipase 
C [46, 47].
Androgen action might be disturbed by alternative splicing [48]. This is a common event 
described in the structural molecular biology of AR genes. Alternative splicing is a process 
by which multiple different mRNAs and downstream proteins can be generated from one 
gene through the inclusion or exclusion of specific exons [49]. This process might occur in 
Figure 1. Schematic representation of the structural and functional domains of AR protein (A) and the coding of exons 
1–8 in relation to each functional domain of human AR gene (B). AF, transcriptional activation function; NLS, nuclear 
localization signal; HSP, heat shock protein.
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95% of all multi-exonic genes and provides a significant advantage in evolution by increas-
ing proteomic diversity [50]. Although deregulation of this process may lead to inappropri-
ate spliced mRNA, impaired proteins and eventually to diseases such as cancers [51, 52] or 
endocrine system dysfunction [53]. More recently, two AR splice variants expressed in GCs 
from patients with polycystic ovary syndrome (PCOS), which is one of the most common 
causes of female infertility, have been identified [54]. The altered AR splicing patterns are 
strongly associated with hyperandrogenism and abnormal folliculogenesis in PCOS [55]. It 
seems possible that AR alternative splicing may be an important pathogenic mechanism in 
human infertility.
Figure 2. Molecular mechanism of the AR action. After entering into the cell, ARs bind to their specific receptors located 
in the cytoplasm; the ligand-receptor complexes are then translocated to the nucleus. After that, they bind to DNA 
as dimmers modulating gene expression (1). Alternatively, the ligand-receptor complexes in the nucleus interact with 
transcription factors, which in turn bind to their responsive elements on the DNA to regulate gene expression (2). 
Hormone-independent mechanism involves AR phosphorylation and activation, which is triggered by protein kinase 
cascade in response to growth factors binding to their receptors located on the cell membrane. Phosphorylated ARs 
enter the nucleus and bind to DNA, regulating gene expression (3). Androgens may also be directly bounded by cell 
membrane receptors, triggering the activation of protein kinase cascades. Thereafter, phosphorylated transcription 
factors bind to their own response elements in the genome, thereby controlling gene expression (4). Androgen action 
might be either mediated by intracellular secondary messengers produced in response to the activation of G-protein-
coupled receptors (5). TF, transcription factor; cAMP, cyclic AMP; PKA, protein kinase A; PLC, phospholipase C; IP
3
, 
inositol 1,4,5-trisphosphate; DAG, diacylglycerol; PKC, protein kinase C.
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3. Androgens and follicular development
In the ovary of a mature mammalian female, the process of folliculogenesis proceeds all 
the time, which manifests in cell proliferation and differentiation. Such a process, involving 
growth and development of ovarian follicles from the stage of primordial to the preovulatory 
ones, is a substantially complicated phenomenon requiring multidirectional regulation. From 
the initial pool of ovarian follicles starting to grow, the preovulatory stage is reached by only 
a few. More than 99% of the follicles undergo atresia at various stages of development. The 
transition from the preantral to an early antral stage is most susceptible to this process. All 
primordial follicles present during fetal life constitute a reserve that cannot increase later on, 
during the postnatal period. Therefore, the very first stages of folliculogenesis, such as forma-
tion of primordial follicles, their recruitment from the resting pool, and then transformation 
into primary ones, are critical for the reproductive cycle of a vertebrate female animal [56]. 
Improper coordination of the primordial follicle formation and activation of their growth may 
disturb folliculogenesis in mature individuals originating infertility.
3.1. Origin of primordial follicles
In the developing ovary, the primordial follicles consist of an oocyte surrounded by a single 
layer of squamous pregranulosa cells. Once assembled, some of the primordial follicles are 
immediately stimulated to growth, but most remain quiescent until selected follicles are gradu-
ally recruited into a growing follicle pool, throughout the reproductive life [57]. The recruit-
ment of primordial follicles into a growth (primordial-to-primary follicle transition) involves 
a change in the shape of the granulosa cells from squamous to cuboidal and the initiation of 
oocyte growth. The primordial-to-primary follicle transition is an irreversible process. The early 
stages of folliculogenesis are believed to be gonadotropin independent. All events related to 
early follicular development are mostly regulated by paracrine growth factors originating from 
the growing oocyte itself and from the somatic cells that surround it [58, 59] and also by ovar-
ian steroid hormones (i.e., progesterone, androgens, and estrogens) [6]. Interestingly, during 
initiation of primordial follicle growth, a fundamental role for androgens has been shown. In 
mouse, bovine and primate ovaries T and DHT [3, 60, 61] are responsible for the stimulation of 
this process, while in sheep DHEA plays the main role [62]. The initiation of primordial follicle 
growth might be mediated through paracrine stimulation, by upregulation of IGF-1 and/or its 
receptor [63]. On the other hand, it seems possible that androgens, acting through ARs, regulate 
the early stages of follicular development. Fowler et al. [61] reported that in human fetal ovaries 
pregranulosa cells express ARs, and the oocytes of the primordial follicles are able to synthe-
size androgens. Taken together, androgens might stimulate the primordial-to-primary follicle 
transition but still an open-ended question is that how they exactly influence primordial follicle 
recruitment and whether this is a primary or secondary response [64].
3.2. Antral follicle formation
Studies indicating AR expression in the different compartments of follicles throughout most 
stages of folliculogenesis allowed us to assume that androgens regulate follicular  development [9]. 
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Although AR expression pattern differs between follicular cell types, it has been observed that AR 
number declines together with follicle maturation to the preovulatory stage [65]. AR-mediated 
actions might be important in the antrum formation during follicular development. Mouse pre-
antral follicles cultured in vitro in the presence of an AR antagonist, bicalutamide, showed sig-
nificantly suppressed growth and antral cavity formation. At the same time, supplementation 
of culture medium with DHT restored the follicular growth and antral development in follicles 
cultured without FSH addition [66]. Similar situation was observed after different androgens 
(incl. T, DHT, or DHEA) in addition to in vitro culture system of mouse preantral follicles. 
They undergone rapid granulosa cell proliferation and amplified responsiveness to FSH [67]. 
Moreover, supplementation of culture media with estrogens, with or without fadrozole (an aro-
matase inhibitor), had no effect on follicular development, while the addition of an AR antago-
nist, flutamide, suppressed follicular growth. These studies allow to state that these androgen 
stimulatory effects on antrum formation and follicular growth are mediated directly through 
ARs and are not induced by T aromatization to estrogens [3]. Our recent research was conducted 
to determine whether experimentally induced androgen deficiency during in vitro culture of 
porcine ovarian cortical slices affects preantral follicular development. Cultured preantral folli-
cles were supplemented with testosterone, nonsteroidal antiandrogen, 2-hydroxyflutamide, and 
a dicarboximide fungicide, separately or in combination with androgen. 2-Hydoxyflutamide is a 
pharmaceutical compound, which is regarded as a model antiandrogen in experimental studies. 
It promotes AR translocation to the nucleus and DNA binding but nevertheless fails to initi-
ate transcription, inhibiting the AR signaling pathway [68]. We demonstrated the deleterious 
effects of androgen deficiency at antrum formation stage, what confirms androgen involvement 
in porcine early follicular development [69]. In summary, it was clearly shown that androgens 
enhance ovarian follicle growth, from preantral to antral stage. The main findings regarding the 
direct action of androgens on the in vivo and in vitro control of follicular development in mam-
mals are based on the transcriptional actions of ARs in follicular cells.
3.3. Preovulatory follicular development
During antrum formation GCs separate into cumulus GCs and mural GCs, which line the fol-
licle wall. These two subpopulations of GCs gain different morphological and functional prop-
erties during further follicle development [70]. The mural granulosa cells are characterized by 
high levels of steroidogenic enzyme activity, which converts androgens to estrogens, while 
the cumulus cells (CCs) are engaged in supporting oocyte growth and maturation. Just before 
ovulation, CCs acquire steroidogenic abilities and start to produce primarily progesterone [71]. 
The role of ARs in the female was elucidated by the studies of various global and tissue-specific 
AR knockout (ARKO) mouse models [72]. Granulosa cell-specific ARKO (GCARKO) mouse 
models have demonstrated that granulosa cells are an important site for androgen action and 
strongly suggested that the AR in these cells is an important regulator of androgen-mediated 
follicular growth and development. On the other hand, AR inactivation in the oocyte, as shown 
in the OoARKO female mouse model, appears to have no major overall effect on female fer-
tility [73]. Using female mice lacking functional ARs (AR−/α), Hu et al. [74] demonstrated 
impaired expression of ovulatory genes, defective morphology of the preovulatory cumu-
lus oophorus cells, and markedly reduced fertility. However, there are contradictory reports 
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concerning androgen effects on oocyte maturation and embryonic development. While some 
authors found androgens exerting inhibitory effects on these processes in different species [75, 
76], others have shown that T increases the cleavage rate of fertilized rat oocytes and that dihy-
drotestosterone improves the fertilizability of mouse oocytes [77, 78]. Optimal androgen levels 
appear to be of real importance in the maintenance of proper preovulatory follicular devel-
opment ensuring normal ovulatory function. Administration of T or DHT did not increase 
preovulatory follicle numbers in primate ovaries [12]. Yet, in pigs, treatment with T or DHT 
during the late follicular phase increased the number of preovulatory follicles and corpora 
lutea [79]. In mice, DHT at a low dose [80] improved the ovulatory response to superovulation. 
Likewise, in vivo treatment of rats with a steroidal AR blocker (cyproterone acetate) leads to 
a decrease in the number of new corpora lutea, indicating an inhibition of ovulation [81]. To 
sum up, these findings indicate that androgens indeed play a role at the preovulatory stage of 
follicle life cycle. Moreover, the coordination of oocyte maturation and ovulation is reactive to 
the androgenic environment. Therefore, a balance of androgen positive and negative actions 
is required for optimal ovarian functioning. Some contradictory findings on the role played by 
androgens in this period of follicle development stress the need for further research aimed at 
elucidating the background of these processes.
4. Antiandrogenic and androgenic EDC action within the ovary
In the light of a dramatic increase of evidences demonstrating the harmful effects of EDCs 
present in the environment, it is crucial for further research on the female reproductive 
potency to understand the mechanisms of their action within ovaries. Among EDCs there is a 
large group of chemicals exerting antiandrogenic effects and blocking endogenous androgen 
action. We can find there pharmaceuticals (e.g. 2-hydroxyflutamide, ketoconazole) as well 
as environmental contaminants: pesticides (e.g. vinclozolin, linuron) or synthetic androgens 
such as testosterone propionate or boldione, which are widely used anabolic steroids [82]. 
During our previous experiments concerning the involvement of androgen in ovarian fol-
licular development and atresia, we generated an in vitro toxicological model for studying 
androgen deficiency. Using 2-hydroxyflutamide, which is a nonsteroidal antiandrogen acting 
at the AR level, we induced distortions of androgen action in the ovary that in consequence 
reduced porcine GC viability and proliferation [83].
Vinclozolin, a commonly used dicarboximide fungicide, is registered in the USA and Europe 
to prevent decay of fruits and vegetables. It was shown that vinclozolin possesses an antian-
drogenic activity in mammals and fish [84–86]. Two major ring-opened metabolites of vin-
clozolin (butenoic acid M1 and enanilide M2) have been detected in rodent fluids and tissue 
extracts following in vivo exposure that might have negative consequences for human health 
[87–89]. Exposure to vinclozolin during gonadal sex determination period in mice promotes a 
transgenerational increase in pregnancy abnormalities and female adult onset malformation 
in the reproductive organs [90, 91]. Our previous studies showed that vinclozolin at an envi-
ronmentally relevant concentration might contribute to the amplification and propagation 
of apoptotic cell death in the granulosa layer, leading to the rapid removal of atretic follicles 
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in porcine ovary [92, 93]. Besides, it seems possible that vinclozolin activates non-genomic 
signaling pathways directly modifying the AR action. Another widely used pesticide with 
antiandrogenic activity is linuron. In vitro studies in mammals demonstrated that linuron 
competitively inhibits the binding of androgens to the ARs [94] and acts as a weak AR antago-
nist in transcriptional activation assays [95]. Additionally, prenatal in vivo exposure to high 
doses of linuron caused reduced testosterone production, altered expression patterns in gene 
involved in tissue morphogenesis, and morphological disruptions to androgen-organized tis-
sues [96–98]. It is currently hypothesized that antiandrogenic pesticides such as vinclozolin 
or linuron act through a mixed mode of action including both AR antagonism and reduced 
testosterone production.
The European Community banned the use of anabolics in Europe by means of laws 
96/22/EC and 96/23/EC. Despite these regulations, in many countries, exogenous sex hor-
mones are widely and illegally used in livestock for anabolic purposes during the last 2 
months of the fattening period. Such deliberate action raised ovarian cancer incidence in 
both adult and young animals [99]. Literature search reveals a positive correlation between 
steroid hormone abuse and cancer incidence [100]. Sex hormones and gonadotropins are 
responsible for the regulation of granulosa cell proliferation and their physiological changes 
with maturation [101]. They stimulate cell growth, even in mutated cells, and this is why 
they are considered cocarcinogens. Thanks to their ability to stimulate mitosis, thus increas-
ing the number of cell divisions, steroids also increase the risk of mutations [102]. Generally, 
some mutations can be corrected by cellular DNA repair mechanisms, but since these pro-
cesses require prolonged times, it is believed that faster cell division increases the risk of 
mutations that can be transferred to daughter cells. Consequently, these hormones may act 
not only as cocarcinogens but also as true carcinogens, being able to provoke an increased 
risk for mutation in their target cells. They also stimulate the divisions of the mutated cells 
[103]. An increased proliferation rate observed in many cell lines indicates that sex steroid 
hormones act as growth factors and activate respective signaling pathways [104]. Although 
this is not a uniform view, it seems that sex steroids interfere with mechanisms controlling 
apoptotic cell death. Regarding androgens, in some experiments, they have been shown to 
promote granulosa cell apoptosis [105], while other authors have affirmed that they pre-
served granulosa cells and follicles from undergoing programmed cell death [106]. Today, 
there is more than 100 varieties of AAS that have been developed, with only a few approved 
for human or veterinary use. They are used not only by athletic competitors and sports-
men but also by people wanting to alter their physical appearance usually based on the 
widespread belief that strong, muscled body is the model for the ideal. Some anabolic sub-
stances, i.e., testosterone propionate, boldione, or nandrolone, are openly available on the 
Internet for use by body builders. The International Agency for Research on Cancer classi-
fies them as probable human carcinogens, with a carcinogenicity index higher than that of 
other androgens such as stanozolol, clostebol, and testosterone [107]. Recently, several mod-
els of primary granulosa cell cultures, originating from different animal species, have been 
devised and are being used to test the effects of EDCs (including anabolic steroids) on cell 
proliferation, steroidogenesis, and neoplastic transformation [108]. Moreover, after in vivo 
exposure of an animal to  testosterone propionate, an increase in primary follicle number 
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together with a decrease in those with antrum was observed, leading to the higher propor-
tion of atretic follicles and the lack of corpora lutea within the ovaries [109]. Following these 
considerations, it should be useful to evaluate the possible involvement of anabolics in the 
follicular cell transformation being this the first step of carcinogenesis. It might be also pos-
sible, in view of the way in which steroids and their derivate act in the mammalian ovary, to 
check if anabolics trigger follicular cell apoptosis, thereby causing PCOS.
5. Conclusions
In the last decades, it was proven that environmental chemical compounds exert toxic and 
genotoxic effects and thus form a serious threat to mammalian reproduction. However, the 
impact of anabolics on ovarian function has been less realized and studied. Recognition and 
evaluation of risk associated with the AAS use are of the utmost importance for human health. 
Harmful effects of compounds with antiandrogenic activities acting during folliculogenesis 
have been shown to affect oocyte survival and follicle growth, as well as steroidogenesis. 
Better understanding of the mechanisms underlying the consequences of the EDC exposure is 
required to implement a risk reduction measures to the health of living organisms and, more 
generally, for a more effective environmental protection activities from chemical pollutants.
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